Bone Marrow-derived Mesenchymal Stem Cell Transplant Survival in the Injured Rodent Spinal Cord

Ritfeld, Gaby J.; Oudega, Martin

doi:10.4172/2329-8820.1000146

Cited by 9 publications

(6 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the major limitations of using MSC to correct the nervous system is their poor survival in unfriendly environments and consequent need to use repeated treatments 7‐11 . In one of our studies, we assessed for the levels of hepatic aminotransferases after repeated transplantation and these were not increased when compared to nontreated or WT mice, indicating absence of liver toxicity in treated mice 8 .…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

“…6 Clinical trials have demonstrated that MSC are safe and promote a favourable course of the disease, but their effects are not as long-lasting as desirable due to poor survival in inhospitable environments or inappropriate therapeutic dosage. [7][8][9][10][11] Researchers have been suggesting ways of counteracting their low endurance with pre-conditioning protocols. 12 Moreover, the use of MSC whole secretome or secreted extracellular vesicles is also being evaluated as valuable alternatives.…”

mentioning

confidence: 99%

“…17 1.1.1 | Limitations and undesirable side effects of MSC in neurological disorders One of the major limitations of using MSC to correct the nervous system is their poor survival in unfriendly environments and consequent need to use repeated treatments. [7][8][9][10][11] In one of our studies, we assessed for the levels of hepatic aminotransferases after repeated transplantation and these were not increased when compared to nontreated or WT mice, indicating absence of liver toxicity in treated mice. 8 Corroborating these findings, clinical studies have also reported the safety of using repeated treatments with MSC.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Mesenchymal stem cells for lysosomal storage and polyglutamine disorders: Possible shared mechanisms

Miranda

2021

Eur J Clin Investigation

View full text Add to dashboard Cite

Background Mesenchymal stem cells' (MSC) therapeutic potential has been investigated for the treatment of several neurodegenerative diseases. The fact these cells can mediate a beneficial effect in different neurodegenerative contexts strengthens their competence to target diverse mechanisms. On the other hand, distinct disorders may share similar mechanisms despite having singular neuropathological characteristics. Methods We have previously shown that MSC can be beneficial for two disorders, one belonging to the groups of Lysosomal Storage Disorders (LSDs) – the Krabbe Disease or Globoid Cell Leukodystrophy, and the other to the family of Polyglutamine diseases (PolyQs) – the Machado‐Joseph Disease or Spinocerebellar ataxia type 3. We gave also input into disease characterization since neuropathology and MSC's effects are intrinsically associated. This review aims at describing MSC's multimode of action in these disorders while emphasizing to possible mechanistic alterations they must share due to the accumulation of cellular toxic products. Results Lysosomal storage disorders and PolyQs have different aetiology and associated symptoms, but both result from the accumulation of undegradable products inside neuronal cells due to inefficient clearance by the endosomal/lysosomal pathway. Moreover, numerous cellular mechanisms that become compromised latter are also shared by these two disease groups. Conclusions Here, we emphasize MSC's effect in improving proteostasis and autophagy cycling turnover, neuronal survival, synaptic activity and axonal transport. LSDs and PolyQs, though rare in their predominance, collectively affect many people and require our utmost dedication and efforts to get successful therapies due to their tremendous impact on patient s' lives and society.

show abstract

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal stem cells for lysosomal storage and polyglutamine disorders: Possible shared mechanisms

Miranda

2021

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…They were demonstrated to be safe but their effects were not always consistent, as preclinical studies suggested. This may be due to poor survival in disease environments and/or because inappropriate therapeutic dosage and route of delivery or inconsistent trial design [ 162 , 163 , 164 , 165 ].…”

Section: Cell Transplantation For Diseases Of the Nervous Systemmentioning

confidence: 99%

Regenerative Neurology and Regenerative Cardiology: Shared Hurdles and Achievements

Mitrečić

Hribljan

Jagečić

et al. 2022

IJMS

View full text Add to dashboard Cite

From the first success in cultivation of cells in vitro, it became clear that developing cell and/or tissue specific cultures would open a myriad of new opportunities for medical research. Expertise in various in vitro models has been developing over decades, so nowadays we benefit from highly specific in vitro systems imitating every organ of the human body. Moreover, obtaining sufficient number of standardized cells allows for cell transplantation approach with the goal of improving the regeneration of injured/disease affected tissue. However, different cell types bring different needs and place various types of hurdles on the path of regenerative neurology and regenerative cardiology. In this review, written by European experts gathered in Cost European action dedicated to neurology and cardiology-Bioneca, we present the experience acquired by working on two rather different organs: the brain and the heart. When taken into account that diseases of these two organs, mostly ischemic in their nature (stroke and heart infarction), bring by far the largest burden of the medical systems around Europe, it is not surprising that in vitro models of nervous and heart muscle tissue were in the focus of biomedical research in the last decades. In this review we describe and discuss hurdles which still impair further progress of regenerative neurology and cardiology and we detect those ones which are common to both fields and some, which are field-specific. With the goal to elucidate strategies which might be shared between regenerative neurology and cardiology we discuss methodological solutions which can help each of the fields to accelerate their development.

show abstract

“…In MSCs, mitogen-activated protein kinases (MAPKs) such as c-Jun N-terminal kinases (JNKs), p38, and extracellular signal-regulated kinases (ERKs) are activated by ROS. This results in the activation of apoptotic proteins and suppression of antiapoptotic signaling pathways [ 126 ], which is one of many reasons why most MSCs do not survive after transplantation [ 127 ]. In in vitro cultures, ROS regulate MSC differentiation into three lineages, namely, adipocyte, osteocyte, and chondrocyte [ 128 ].…”

Section: Cell-based Therapeutic Strategies Against Oxidative Stresmentioning

confidence: 99%

Therapeutic Strategies for Oxidative Stress‐Related Cardiovascular Diseases: Removal of Excess Reactive Oxygen Species in Adult Stem Cells

Kim

Yun

Kwon

2016

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Accumulating evidence indicates that acute and chronic uncontrolled overproduction of oxidative stress-related factors including reactive oxygen species (ROS) causes cardiovascular diseases (CVDs), atherosclerosis, and diabetes. Moreover ROS mediate various signaling pathways underlying vascular inflammation in ischemic tissues. With respect to stem cell-based therapy, several studies clearly indicate that modulating antioxidant production at cellular levels enhances stem/progenitor cell functionalities, including proliferation, long-term survival in ischemic tissues, and complete differentiation of transplanted cells into mature vascular cells. Recently emerging therapeutic strategies involving adult stem cells, including endothelial progenitor cells (EPCs), for treating ischemic CVDs have highlighted the need to control intracellular ROS production, because it critically affects the replicative senescence of ex vivo expanded therapeutic cells. Better understanding of the complexity of cellular ROS in stem cell biology might improve cell survival in ischemic tissues and enhance the regenerative potentials of transplanted stem/progenitor cells. In this review, we will discuss the nature and sources of ROS, drug-based therapeutic strategies for scavenging ROS, and EPC based therapeutic strategies for treating oxidative stress-related CVDs. Furthermore, we will discuss whether primed EPCs pretreated with natural ROS-scavenging compounds are crucial and promising therapeutic strategies for vascular repair.

show abstract

Bone Marrow-derived Mesenchymal Stem Cell Transplant Survival in the Injured Rodent Spinal Cord

Cited by 9 publications

References 63 publications

Mesenchymal stem cells for lysosomal storage and polyglutamine disorders: Possible shared mechanisms

Mesenchymal stem cells for lysosomal storage and polyglutamine disorders: Possible shared mechanisms

Regenerative Neurology and Regenerative Cardiology: Shared Hurdles and Achievements

Therapeutic Strategies for Oxidative Stress‐Related Cardiovascular Diseases: Removal of Excess Reactive Oxygen Species in Adult Stem Cells

Contact Info

Product

Resources

About